Top

Published in:

Open Access 05-04-2023 | Alzheimer's Disease | REVIEW

Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022

Authors: Carla Abdelnour, Maria Camila Gonzalez, Lucy L. Gibson, Kathleen L. Poston, Clive G. Ballard, Jeffrey L. Cummings, Dag Aarsland

Published in: Neurology and Therapy | Issue 3/2023

Abstract

Introduction

Reviews of randomized clinical trials (RCTs) in dementia with Lewy bodies (DLB) are essential for informing ongoing research efforts of symptomatic therapies and potentially disease-modifying therapies (DMTs).

Methods

We performed a systematic review of all clinical trials conducted until September 27, 2022, by examining 3 international registries: ClinicalTrials.gov, the European Union Drug Regulating Authorities Clinical Trials Database, and the International Clinical Trials Registry Platform, to identify drugs in trials in DLB.

Results

We found 25 agents in 40 trials assessing symptomatic treatments and DMTs for DLB: 7 phase 3, 31 phase 2, and 2 phase 1 trials. We found an active pipeline for drug development in DLB, with most ongoing clinical trials in phase 2. We identified a recent trend towards including participants at the prodromal stages, although more than half of active clinical trials will enroll mild to moderate dementia patients. Additionally, repurposed agents are frequently tested, representing 65% of clinical trials.

Conclusion

Current challenges in DLB clinical trials include the need for disease-specific outcome measures and biomarkers, and improving representation of global and diverse populations.

Available only for authorised users

Vann Jones SA, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673–83. https://doi.org/10.1017/S0033291713000494.CrossRefPubMed

Garcia-Ptacek S, Farahmand B, Kareholt I, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis. 2014;41(2):467–77. https://doi.org/10.3233/JAD-131856.CrossRefPubMed

Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017;16(5):390–8. https://doi.org/10.1016/s1474-4422(17)30074-1.CrossRefPubMed

Oesterhus R, Soennesyn H, Rongve A, Ballard C, Aarsland D, Vossius C. Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer’s disease and Lewy body dementia. Dement Geriatr Cogn Disord. 2014;38(3–4):161–9. https://doi.org/10.1159/000358051.CrossRefPubMed

Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67(11):1935–41. https://doi.org/10.1212/01.wnl.0000247041.63081.98.CrossRefPubMed

Mueller C, Perera G, Rajkumar AP, et al. Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. Alzheimers Dement (Amst). 2018;10:143–52. https://doi.org/10.1016/j.dadm.2017.12.001.CrossRefPubMed

Rabinovici GD. Controversy and progress in alzheimer’s disease—FDA approval of aducanumab. N Engl J Med. 2021;385(9):771–4. https://doi.org/10.1056/NEJMp2111320.CrossRefPubMed

Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opin Investig Drugs. 2019;28(11):951–65. https://doi.org/10.1080/13543784.2019.1681398.CrossRefPubMedPubMedCentral

Taylor J-P, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157–69. https://doi.org/10.1016/s1474-4422(19)30153-x.CrossRefPubMed

10.

Pope ED, Cordes L, Shi J, Mari Z, Decourt B, Sabbagh MN. Dementia with Lewy bodies: emerging drug targets and therapeutics. Expert Opin Investig Drugs. 2021;30(6):603–9. https://doi.org/10.1080/13543784.2021.1916913.CrossRefPubMedPubMedCentral

11.

MacDonald S, Shah AS, Tousi B. Current therapies and drug development pipeline in lewy body dementia: an update. Drugs Aging. 2022;39(7):505–22. https://doi.org/10.1007/s40266-022-00939-w.CrossRefPubMed

12.

Cummings J, Lee G, Nahed P, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295. https://doi.org/10.1002/trc2.12295

13.

McFarthing K, Rafaloff G, Baptista M, et al. Parkinson’s disease drug therapies in the clinical trial pipeline: 2022 update. J Parkinsons Dis. 2022;12(4):1073–82. https://doi.org/10.3233/JPD-229002.CrossRefPubMedPubMedCentral

14.

O’Brien JT, Chouliaras L, Sultana J, et al. RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus. Alzheimer’s Res Therapy. 2022;14(1):169. https://doi.org/10.1186/s13195-022-01103-7.CrossRef

15.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Accessed February 18, 2023. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf

16.

Fagiani F, Lanni C, Racchi M, Govoni S. Targeting dementias through cancer kinases inhibition. Alzheimers Dement (N Y). 2020;6(1):e12044. https://doi.org/10.1002/trc2.12044

17.

Goldfine A, Faulkner R, Sadashivam V, et al. Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson’s Disease. Neurology. 2019;92(15 Supplement):P2.8–047.

18.

Mahdavi KD, Jordan SE, Barrows HR, et al. Treatment of dementia with bosutinib: an open-label study of a tyrosine kinase inhibitor. Neurol Clin Pract. 2021;11(3):e294–302. https://doi.org/10.1212/CPJ.0000000000000918.CrossRefPubMedPubMedCentral

19.

Pagan FL, Torres-Yaghi Y, Hebron ML, et al. Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. Alzheimers Dement (N Y). 2022;8(1):e12296. https://doi.org/10.1002/trc2.12296

20.

Limegrover CS, Yurko R, Izzo NJ, et al. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain-derived alpha-synuclein. J Neurosci Res. 2021;99(4):1161–76. https://doi.org/10.1002/jnr.24782.CrossRefPubMedPubMedCentral

21.

Moebius H, Hua X, Church K, et al. Phase 1 study of NDX-1017: safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and dementia patients. J Prev Alzheimer’s Dis. 2019;6(S22)

22.

Takeuchi D, Sato N, Shimamura M, et al. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008;15(8):561–71. https://doi.org/10.1038/sj.gt.3303094.CrossRefPubMed

23.

Balestrino R, Schapira AHV. Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications. Neuroscientist. 2018;24(5):540–59. https://doi.org/10.1177/1073858417748875.CrossRefPubMed

24.

Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8. https://doi.org/10.1016/s1474-4422(09)70146-2.CrossRefPubMed

25.

Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77. https://doi.org/10.1016/s1474-4422(10)70194-0.CrossRefPubMed

26.

Cummings J, Bauzon J, Lee G. Who funds Alzheimer's disease drug development? Alzheimers Dement (N Y). 2021;7(1):e12185. https://doi.org/10.1002/trc2.12185

27.

Rodriguez-Porcel F, Wyman-Chick KA, Abdelnour Ruiz C, et al. Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Transl Neurodegener. 2022;11(1):24. https://doi.org/10.1186/s40035-022-00299-w.CrossRefPubMedPubMedCentral

28.

Lee DR, McKeith I, Mosimann U, et al. The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia. Am J Geriatr Psychiatry. 2014;22(9):926–35. https://doi.org/10.1016/j.jagp.2013.01.072.CrossRefPubMed

29.

Jiang Y, Alam JJ, Gomperts SN, et al. Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nature Communications. 2022;13(1)https://doi.org/10.1038/s41467-022-32944-3

30.

Biglan K, Munsie L, Svensson KA, et al. Safety and efficacy of mevidalen in lewy body dementia: a phase 2, randomized. Placebo-Controlled Trial Mov Disord. 2022;37(3):513–24. https://doi.org/10.1002/mds.28879.CrossRefPubMed

31.

McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743–55. https://doi.org/10.1212/WNL.0000000000009323.CrossRefPubMedPubMedCentral

32.

Toledo JB, Abdelnour C, Weil RS, et al. Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design. Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12814.CrossRefPubMed

33.

Thomas AJ, Mahin-Babaei F, Saidi M, et al. Improving the identification of dementia with Lewy bodies in the context of an Alzheimer’s-type dementia. Alzheimers Res Ther. 2018;10(1):27. https://doi.org/10.1186/s13195-018-0356-0.CrossRefPubMedPubMedCentral

34.

Lu CC, Li XN, Broglio K, et al. Practical considerations and recommendations for master protocol framework: basket, umbrella and platform trials. Ther Innov Regul Sci. 2021;55(6):1145–54. https://doi.org/10.1007/s43441-021-00315-7.CrossRefPubMed

35.

Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698. https://doi.org/10.1136/bmj.k698

36.

Adaptive Designs for Clinical Trials of Drugs and Biologics. Guidance for industry (Food and Drug Administration) (2019).

37.

Cummings J, Montes A, Kamboj S, Cacho JF. The role of basket trials in drug development for neurodegenerative disorders. Alzheimers Res Ther. 2022;14(1):73. https://doi.org/10.1186/s13195-022-01015-6.CrossRefPubMedPubMedCentral

38.

D'Antonio F, Kane JPM, Ibanez A, et al. Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. Alzheimers Dement (Amst). 2021;13(1):e12235. https://doi.org/10.1002/dad2.12235

39.

Goldman JG, Forsberg LK, Boeve BF, et al. Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimers Res Ther. 2020;12(1):137. https://doi.org/10.1186/s13195-020-00703-5.CrossRefPubMedPubMedCentral

40.

Peterson B, Armstrong M, Galasko D, et al. Lewy body Dementia association’s research centers of excellence program: inaugural meeting proceedings. Alzheimers Res Ther. 2019;11(1):23. https://doi.org/10.1186/s13195-019-0476-1.CrossRefPubMedPubMedCentral

41.

McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry. 2000;15(5):387–92. https://doi.org/10.1002/(sici)1099-1166(200005)15:5%3c387::Aid-gps131%3e3.0.Co;2-9.CrossRefPubMed

42.

McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. The Lancet. 2000;356(9247):2031–6. https://doi.org/10.1016/s0140-6736(00)03399-7.CrossRef

Title: Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022
Authors: Carla Abdelnour
Maria Camila Gonzalez
Lucy L. Gibson
Kathleen L. Poston
Clive G. Ballard
Jeffrey L. Cummings
Dag Aarsland
Publication date: 05-04-2023
Publisher: Springer Healthcare
Keywords: Alzheimer's Disease
Dementia
Alzheimer's Disease
Dementia
Published in: Neurology and Therapy / Issue 3/2023
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-023-00467-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

Frameless Robot-Assisted Asleep Centromedian Thalamic Nucleus Deep Brain Stimulation Surgery in Patients with Drug-Resistant Epilepsy: Technical Description and Short-Term Clinical Results

Design of a Non-Interventional Study to Assess Neurologists’ Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease

Familial Mediterranean Fever and Transverse Myelitis: A Causal Relation?

Podcast on the Art of the Patient Conversation: Healthcare Provider Perspectives to Improve Outcomes in Multiple Sclerosis

Optimizing The Timing of Stereotactic Minimally Invasive Drainage for Hypertensive Intracerebral Hemorrhage

Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects